Editing Adenosine (section)

=== Anti-inflammatory properties ===
Adenosine is believed to be an [[anti-inflammatory]] agent at the A<sub>2A</sub> receptor.<ref name="pmid18461129">{{Cite journal | vauthors = Nakav S, Chaimovitz C, Sufaro Y, Lewis EC, Shaked G, Czeiger D, Zlotnik M, Douvdevani A | title = Anti-inflammatory preconditioning by agonists of adenosine A1 receptor | journal = PLOS ONE | volume = 3 | issue = 5 | pages = e2107 | date = May 2008 | pmid = 18461129 | pmc = 2329854 | doi = 10.1371/journal.pone.0002107 | veditors = Bozza P | doi-access = free | bibcode = 2008PLoSO...3.2107N }}</ref><ref name="pmid18846036">{{Cite journal | vauthors = Trevethick MA, Mantell SJ, Stuart EF, Barnard A, Wright KN, Yeadon M | title = Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions | journal = British Journal of Pharmacology | volume = 155 | issue = 4 | pages = 463–474 | date = October 2008 | pmid = 18846036 | pmc = 2579671 | doi = 10.1038/bjp.2008.329 }}</ref> Topical treatment of adenosine to foot wounds in [[diabetes mellitus]] has been shown in lab animals to drastically increase tissue repair and reconstruction. Topical administration of adenosine for use in wound-healing deficiencies and diabetes mellitus in humans is currently under clinical investigation.

[[Methotrexate]]'s anti-inflammatory effect may be due to its stimulation of adenosine release.<ref name="pmid21044428">{{Cite journal | vauthors = Cronstein B | title = How does methotrexate suppress inflammation? | journal = Clinical and Experimental Rheumatology | volume = 28 | issue = 5 Suppl 61 | pages = S21–S23 | year = 2010 | pmid = 21044428 }}</ref>